Literature DB >> 25820675

Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Agnese Picco1, Silvia Morbelli, Arnoldo Piccardo, Dario Arnaldi, Nicola Girtler, Andrea Brugnolo, Irene Bossert, Lucio Marinelli, Antonio Castaldi, Fabrizio De Carli, Claudio Campus, Giovanni Abbruzzese, Flavio Nobili.   

Abstract

PURPOSE: The role of mesocortical dopaminergic pathways in the cognitive function of patients with early Parkinson's disease (PD) needs to be further clarified.
METHODS: The study groups comprised 15 drug-naive patients with de novo PD and 10 patients with essential tremor (controls) who underwent (18)F-DOPA PET (static acquisition, normalization on mean cerebellar counts) and an extended neuropsychological test battery. Factor analysis with varimax rotation was applied to the neuropsychological test scores, to yield five factors from 16 original scores, which explained 82 % of the total variance. Correlations between cognitive factors and (18)F-DOPA uptake were assessed with SPM8, taking age and gender as nuisance variables.
RESULTS: (18)F-DOPA uptake was significantly lower in PD patients than in controls in the bilateral striatum, mainly in the more affected (right) hemisphere, and in a small right temporal region. Significant positive correlations were found only in PD patients between the executive factor and (18)F-DOPA uptake in the bilateral anterior cingulate cortex (ACC) and the middle frontal gyrus, between the verbal fluency factor and (18)F-DOPA uptake in left BA 46 and the bilateral striatum, and between the visuospatial factor and (18)F-DOPA uptake in the left ACC and bilateral striatum. No correlations were found between (18)F-DOPA uptake and either the verbal memory factor or the abstraction-working memory factor.
CONCLUSION: These data clarify the role of the mesocortical dopaminergic pathways in cognitive function in early PD, highlighting the medial frontal lobe, anterior cingulate, and left BA 46 as the main sites of cortical correlation with executive and language functions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820675     DOI: 10.1007/s00259-015-3039-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  56 in total

1.  A classification of hand preference by association analysis.

Authors:  M Annett
Journal:  Br J Psychol       Date:  1970-08

Review 2.  Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates.

Authors:  B Berger; P Gaspar; C Verney
Journal:  Trends Neurosci       Date:  1991-01       Impact factor: 13.837

3.  Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.

Authors:  T Ishikawa; V Dhawan; T Chaly; C Margouleff; W Robeson; J R Dahl; F Mandel; P Spetsieris; D Eidelberg
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

4.  Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.

Authors:  Pekka Jokinen; Hans Helenius; Elina Rauhala; Anna Brück; Olli Eskola; Juha O Rinne
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

5.  Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study.

Authors:  Flavio Nobili; Claudio Campus; Dario Arnaldi; Fabrizio De Carli; Gaia Cabassi; Andrea Brugnolo; Barbara Dessi; Silvia Morbelli; Gianmario Sambuceti; Giovanni Abbruzzese; Guido Rodriguez
Journal:  Mov Disord       Date:  2010-01-15       Impact factor: 10.338

Review 6.  Neurotransmission in Parkinson's disease: beyond dopamine.

Authors:  P Barone
Journal:  Eur J Neurol       Date:  2009-12-30       Impact factor: 6.089

7.  Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.

Authors:  Atsuko Nagano-Saito; Takashi Kato; Yutaka Arahata; Yukihiko Washimi; Akinori Nakamura; Yuji Abe; Takako Yamada; Katsushige Iwai; Kentaro Hatano; Yasuhiro Kawasumi; Teruhiko Kachi; Alain Dagher; Kengo Ito
Journal:  Neuroimage       Date:  2004-06       Impact factor: 6.556

8.  Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction.

Authors:  Pekka Jokinen; Mira Karrasch; Anna Brück; Jarkko Johansson; Jörgen Bergman; Juha O Rinne
Journal:  J Neurol Sci       Date:  2013-04-03       Impact factor: 3.181

Review 9.  PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.

Authors:  Yoshitaka Kumakura; Paul Cumming
Journal:  Neuroscientist       Date:  2009-12       Impact factor: 7.519

Review 10.  Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.

Authors:  Angie A Kehagia; Roger A Barker; Trevor W Robbins
Journal:  Neurodegener Dis       Date:  2012-10-03       Impact factor: 2.977

View more
  9 in total

1.  The role of the deep convolutional neural network as an aid to interpreting brain [18F]DOPA PET/CT in the diagnosis of Parkinson's disease.

Authors:  Arnoldo Piccardo; Roberto Cappuccio; Gianluca Bottoni; Diego Cecchin; Luca Mazzella; Alessio Cirone; Sergio Righi; Martina Ugolini; Pietro Bianchi; Pietro Bertolaccini; Elena Lorenzini; Michela Massollo; Antonio Castaldi; Francesco Fiz; Laura Strada; Angelina Cistaro; Massimo Del Sette
Journal:  Eur Radiol       Date:  2021-03-08       Impact factor: 5.315

2.  Multidelay multiparametric arterial spin labeling perfusion MRI and mild cognitive impairment in early stage Parkinson's disease.

Authors:  Xueling Suo; Du Lei; Lan Cheng; Nannan Li; Panli Zuo; Danny J J Wang; Xiaoqi Huang; Su Lui; Graham J Kemp; Rong Peng; Qiyong Gong
Journal:  Hum Brain Mapp       Date:  2018-12-07       Impact factor: 5.038

Review 3.  N200 and P300 component changes in Parkinson's disease: a meta-analysis.

Authors:  Hui Xu; Lihua Gu; Shiyao Zhang; Yuchen Wu; Xiaojin Wei; Caiyan Wang; Yuhan Xu; Yijing Guo
Journal:  Neurol Sci       Date:  2022-08-18       Impact factor: 3.830

4.  Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese-Exposed Workers.

Authors:  Susan R Criswell; Susan Searles Nielsen; Wendy W Dlamini; Mark N Warden; Joel S Perlmutter; Lianne Sheppard; Stephen M Moerlein; Jason Lenox-Krug; Harvey Checkoway; Brad A Racette
Journal:  Toxicol Sci       Date:  2021-07-16       Impact factor: 4.849

5.  Progressive brain atrophy in Parkinson's disease patients who convert to mild cognitive impairment.

Authors:  Cheng Zhou; Xiao-Jun Guan; Tao Guo; Qiao-Ling Zeng; Ting Gao; Pei-Yu Huang; Min Xuan; Quan-Quan Gu; Xiao-Jun Xu; Min-Ming Zhang
Journal:  CNS Neurosci Ther       Date:  2019-07-06       Impact factor: 5.243

6.  Hybrid PET-MRI for early detection of dopaminergic dysfunction and microstructural degradation involved in Parkinson's disease.

Authors:  Song'an Shang; Daixin Li; Youyong Tian; Rushuai Li; Hongdong Zhao; Liyun Zheng; Yingdong Zhang; Yu-Chen Chen; Xindao Yin
Journal:  Commun Biol       Date:  2021-10-07

7.  Metabolite changes in prefrontal lobes and the anterior cingulate cortex correlate with processing speed and executive function in Parkinson disease patients.

Authors:  Chentao He; Siming Rong; Piao Zhang; Ruitao Li; Xiaohong Li; Yan Li; Lijuan Wang; Yuhu Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-08

8.  Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease.

Authors:  Brenna A Cholerton; Kathleen L Poston; Laurice Yang; Liana S Rosenthal; Ted M Dawson; Alexander Pantelyat; Karen L Edwards; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Thomas J Montine; Cyrus P Zabetian
Journal:  J Clin Exp Neuropsychol       Date:  2021-08-06       Impact factor: 2.283

9.  Topologically convergent and divergent morphological gray matter networks in early-stage Parkinson's disease with and without mild cognitive impairment.

Authors:  Xueling Suo; Du Lei; Nannan Li; Junying Li; Jiaxin Peng; Wenbin Li; Jing Yang; Kun Qin; Graham J Kemp; Rong Peng; Qiyong Gong
Journal:  Hum Brain Mapp       Date:  2021-07-28       Impact factor: 5.038

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.